Fidelis Pharmaceuticals
North Brunswick, US · Delaware corporation
Find your way into Fidelis Pharmaceuticals
Sign up to see every warm intro you have to Fidelis Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Fidelis Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
BL
Barry LevinsonNamed on SEC filing
DS
Dennis SteadmanNamed on SEC filing
CD
Cynthia DavisNamed on SEC filing
SW
Susan WithamNamed on SEC filing
SL
Steven LearyNamed on SEC filing
AM
Andrew MidlerNamed on SEC filing
KS
Kenneth SylvesterNamed on SEC filing
ES
Eric SchreiberNamed on SEC filing
MW
Michael WellsNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$6.1M disclosed across 2 rounds · 2021–2024
▶$1MraisedFeb 2024 · 10 investors · PharmaceuticalsRule 506(b)
▶$1MraisedFeb 2024 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew MidlerDirector
- Michael WellsExecutive Officer, Director, Promoter
- Susan WithamExecutive Officer
- Dennis SteadmanDirector
- Steven LearyExecutive Officer
- Barry LevinsonExecutive Officer, Director, Promoter
- Cynthia DavisExecutive Officer
- Offering amount
- $2M
- Amount sold
- $1M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedJul 2021 · 8 investors · PharmaceuticalsRule 506(b)
▶$5.1MraisedJul 2021 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Barry LevinsonExecutive Officer, Director, Promoter
- Dennis SteadmanDirector
- Cynthia DavisExecutive Officer
- Susan WithamExecutive Officer
- Steven LearyExecutive Officer
- Andrew MidlerDirector
- Kenneth SylvesterExecutive Officer
- Eric SchreiberExecutive Officer
- Michael WellsExecutive Officer, Director, Promoter
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Fidelis Pharmaceuticals raised?
- Fidelis Pharmaceuticals has disclosed $6.1M raised across 2 rounds.
- Where is Fidelis Pharmaceuticals headquartered?
- Fidelis Pharmaceuticals is headquartered in North Brunswick, US.